Abstracts Archive - Page 1890 of 2607 - ACR Meeting Abstracts

Abstract Number: 280 • 2015 ACR/ARHP Annual Meeting
The Fascia Is a Target Organ of Inflammation in Autoimmune Diseases
Kentaro Noda, Ken Yoshida, Taro Ukichi, Kazuhiro Furuya, Kenichiro Hirai, Isamu Kingetsu and Daitaro Kurosaka, Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: We previously reported that inflammation occurred early in the fascia of patients with dermatomyositis. We often encounter patients with autoimmune diseases who present with…
Abstract Number: 281 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life Is Reduced in Adult Patients with Idiopathic Inflammatory Myopathies
Michal Feldon¹, Payam Noroozi Farhadi², Hermine I. Brunner¹, Lukasz Itert³, Bob Goldberg⁴, Abdullah Faiq², Jesse Wilkerson⁵, Kathryn Rose⁵, Frederick W. Miller², Lisa G Rider² and Edward H. Giannini⁶, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴The Myositis Association, Alexandria, VA, ⁵Social and Scientific Systems, Inc., Durham, NC, ⁶Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Idiopathic inflammatory myopathies (IIM), such as dermatomyositis (DM), polymyositis (PM) and inclusion body myositis (IBM), are chronic multi-systemic inflammatory conditions. Substantial studies on health…
Abstract Number: 282 • 2015 ACR/ARHP Annual Meeting
Angiogenesis in Fasciitis Associated with Dermatomyositis
Ken Yoshida, Kentaro Noda, Taro Ukichi, Kazuhiro Furuya, Kenichiro Hirai, Isamu Kingetsu and Daitaro Kurosaka, Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: We have previously demonstrated that fasciitis is a common lesion of dermatomyositis (DM) detectable early after disease onset. Furthermore, en bloc biopsy showed that the…
Abstract Number: 283 • 2015 ACR/ARHP Annual Meeting
Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
Joan Raouf¹, Helena Idborg¹, Petter Olsson², Per Johan Jakobsson¹, Ingrid E. Lundberg¹ and Marina Korotkova¹, ¹Medicine, Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet S-171 76, Stockholm, Sweden, Stockholm, Sweden, ²Analytical Chemistry, Department of Analytical Chemistry, Stockholm University, Sweden, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases, characterized by muscle fatigue. Despite conventional immunosuppressive treatment including high doses of glucocorticoids, only a…
Abstract Number: 284 • 2015 ACR/ARHP Annual Meeting
Validation of the Sporadic Inclusion Body Myositis Physical Functioning Assessment
Valerie Williams¹, Theresa Coles², Carla DeMuro², Sandra Lewis², Nicole Williams², Stuart Yarr², Victoria Barghout³, Linda Lowes⁴, Lindsay Alfano⁴, Bob Goldberg⁵, Ari Gnanasakthy², Gorana Capkun-Niggli⁶ and Brian Tseng⁷, ¹Psychometrics, RTI Health Solutions, North Carolina, NC, ²RTI Health Solutions, North Carolina, NC, ³VEB HealthCare LLC, Morristown, NJ, ⁴Nationwide Children’s Hospital, Columbus, OH, ⁵The Myositis Association, Alexandria, VA, ⁶Novartis Pharmaceuticals Corporation, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Patient-reported outcomes (PROs) assess disease symptoms and impact from the patient’s perspective. This research aimed to establish the validity, reliability, and responsiveness of the…
Abstract Number: 285 • 2015 ACR/ARHP Annual Meeting
Tobacco Smoking in Different Racial Groups Is Differentially Associated with the Development of Myositis Autoantibodies and Interstitial Lung Disease in the Idiopathic Inflammatory Myopathies
Adam Schiffenbauer¹, Natalie Smith², Lisa G Rider¹ and Frederick W. Miller³, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Statistics, Purdue University, Allison Park, PA, ³Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD
Background/Purpose: Smoking has been found to be a risk or protective factor in certain autoimmune diseases. Yet, its role in the idiopathic inflammatory myopathies (IIM)…
Abstract Number: 287 • 2015 ACR/ARHP Annual Meeting
Interleukin-35 in Idiopathic Inflammatory Myopathies
Herman F. Mann¹, Hana Hulejova^2,3, Josef Zámecník⁴, Jaromir Hacek⁵, Mária Filková⁶, Olga Kryštufková⁷, J Vencovsky⁸ and Ladislav Senolt⁹, ¹Department of Experimental Rheumatology, Institute of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague 2, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ³1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁴Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, ⁵Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁷Institute of Rheumatology, Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁸Institute of Rheumatology, Charles University, Prague, Czech Republic, ⁹Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Interleukin-35 (IL-35) is a newly described heterodimeric cytokine that belongs to the IL-12 family and consists of p35 (IL-12a) and EBI3 (IL-27b) subunits. IL-35…
Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Niharika Sharma¹, Anisha Dua¹, Michael Putman², Rekha Vij³ and Mary Strek³, ¹Rheumatology, The University of Chicago, Chicago, IL, ²Internal Medicine, The University of Chicago, Chicago, IL, ³Pulmonology, The University of Chicago, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…
Abstract Number: 289 • 2015 ACR/ARHP Annual Meeting
Evaluation of Usefulness of Krebs Von Den Lungen-6 As a Biomarker of Interstitial Lung Disease with Polymyositis and Dermatomyositis Including in the Short Time Course after Treatment
Masanori Hanaoka, Yasuhiro Katsumata, Yasushi Kawaguchi, Hidenaga Kawasumi, Hisae Terajima-Ichida, Kae Takagi, Akiko Tochimoto, Yuki Ichimura and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Because of the extremely variable incidence and outcome of interstitial lung disease (ILD) in polymyositis/dermatomyositis (PM/DM), explorationand validation of biomarkers for diagnosis, prognosis, and response…
Abstract Number: 290 • 2015 ACR/ARHP Annual Meeting
Cancer and Necrotizing Immune Mopathy: High Incidence in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive and Seronegative Patients but Not in Anti-Single Recognition Particle Positive Patients
Yves Allenbach¹, Jeremy Kaeren¹, Nicolas Champtiaux¹, Yoland Schoindre¹, Kuberaka Mariampillai¹, Aude Rigolet¹, Lucile Musset², Jean- Luc Charuel², Anthony Behin³, Bruno Eymard⁴, Pascal Laforet⁵, Tanya Stojkovic⁵, Olivier Boyer⁶, Baptiste Hervier⁷ and Olivier Benveniste¹, ¹Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ²Laboratoire d'immunochimie, Pitié- Salpêtrière, Paris, France, ³Institute of Myology, Pitie-Salpetriere Hospital, Paris, France, ⁴Department of Neurology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ⁵Department of Neurology, Myology Institute, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University, Paris, France, ⁶Immunology, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ⁷Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, Paris, France
Background/Purpose: Twenty percent of inflammatory myopathy are associated with a synchronous cancer occurring ±3 years around the diagnosis. Malignancy is a major cause of mortality…
Abstract Number: 291 • 2015 ACR/ARHP Annual Meeting
Correlations Between Muscle-MRI, Muscle Strength and Creatine Kinase Levels in the Anti-Synthetase Syndrome; A Comparative, Cross-Sectional Study
Helena Andersson¹, Eva Kirkhus², Else Merckoll², Ragnhild Walle-Hansen³ and Øyvind Molberg¹, ¹Department of Rheumatology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway, ²Department of Radiology, Oslo University Hospital, Oslo, Norway, ³Department of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway
Background/Purpose: Muscle MRI is used to describe the myositis component of the anti-synthetase syndrome (ASS), but the value of the examination is limited by lack…
Abstract Number: 292 • 2015 ACR/ARHP Annual Meeting
Neoepitope Biomarkers As Biomarkers of Polymyositis and Dermatomyositis and Functional Status
Anders Nedergaard¹, Kim Henriksen², Morten Asser Karsdal³, Wendy White⁴ and Xiang Guo⁴, ¹Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, Copenhagen NW, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are inflammatory conditions characterized by persistent inflammation of muscle tissue (and for DM also skin). Myositis has been shown…
Abstract Number: 293 • 2015 ACR/ARHP Annual Meeting
Measurement of Advanced Glycation Endproducts in the Skin of Patients with Idiopathic Inflammatory Myopathies
Simone Barsotti¹, Chiara Saponaro², Rosaria Talarico³, Alessandra Tripoli⁴, Claudia Ferrari⁵, Elisabetta Bianchini⁶, Nicole Di Lascio⁶, Melania Gaggini², Amalia Gastaldelli², Marta Mosca⁷, Maria Aurora Morales⁶ and Rossella Neri⁵, ¹Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²National Research Council, Institute of Clinical Physiology, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵Internal Medicine, University of Pisa, Pisa, Italy, ⁶Institute of Clinical Physiology, CNR, Pisa, Italy, ⁷University of Pisa, Pisa, Italy
Background/Purpose: Many data suggest that advanced glycation endproducts (AGEs) play an important role the development of atherosclerosis and cardiovascular (CV) disease. AGEs are produced and…
Abstract Number: 294 • 2015 ACR/ARHP Annual Meeting
A Decline in Pulmonary Function over One Year Predicts Outcome in Myositis-Associated Interstitial Lung Disease
Melissa B. Blom¹, Chester V. Oddis², Diane Koontz³ and Rohit Aggarwal⁴, ¹Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in myositis. Clinical trials in myositis-associated ILD (MA-ILD) are lacking due to the absence…
Abstract Number: 295 • 2015 ACR/ARHP Annual Meeting
Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index Among Dermatologists, Rheumatologists, and Neurologists
Neelam Khan^1,2, Janice Tiao^1,2, Rui Feng³, Shawn Bird⁴, Juliana Choi¹, Michael George⁵, Tania Gonzalez-Rivera⁵, Jacob L. Kaufman⁴, Jin Jun Luo⁶, Robert Micheletti¹, Aimee S. Payne¹, Raymond Price⁴, Adam I. Rubin⁷, Antoine G. Sreih⁸, Preethi Thomas⁵, Joyce Okawa⁷ and Victoria P. Werth^1,9, ¹Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Philadelphia V.A. Medical Center, Philadelphia, PA, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁶Department of Neurology, Temple University School of Medicine, Philadelphia, PA, ⁷Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁸Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Philadelphia V.A. Medical Center, Philidelphia, PA
Background/Purpose: Previous studies have shown that skin lesions in dermatomyositis (DM) are best assessed using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). Although…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].